The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis

Abstract

The use of an antibiotic with immunomodulatory properties could be fascinating in treating multifactorial inflammatory conditions such as ulcerative colitis (UC). We report our investigations into the immunomodulatory properties of levornidazole, the S-enantiomer of ornidazole, which displayed a tremendous therapeutic potential in UC induced by dextran sodium sulfate (DSS). Levornidazole administration to DSS-colitic mice attenuated the intestinal inflammatory process, with an efficacy better than that shown by 5-amino salicylic acid. This was evidenced by decreased disease activity index, ameliorated macroscopic and microscopic colon damages, and reduced expression of inflammatory cytokines. Additionally, levornidazole displayed anti-inflammatory activity through Caveolin-1-dependent reducing IL-1β and IL-18 secretion by macrophages contributing to its improvement of the intestinal inflammation, as confirmed in vitro and in vivo. In conclusion, these results pointed out that the immunomodulatory effects of levornidazole played a vital role in ameliorating the intestinal inflammatory process, which would be crucial for the translation of its use into clinical settings.

Keywords

levornidazole / immunomodulatory antibiotic / ulcerative colitis / Caveolin-1 / macrophage

References

[1] ConradK, RoggenbuckD, LaassMW. Diagnosis and classification of ulcerative colitis. Autoimmun, 2014, 13(4–5): 463-466

[2] EisensteinM. Ulcerative colitis: towards remission. Nature, 2018, 563(7730): S33

[3] OrdásI, EckmannL, TalaminiM, et al.. Ulcerative colitis. Lancet, 2012, 380(9853): 1606-1619

[4] Garrido-MesaJ, Rodríguez-NogalesA, AlgieriF, et al.. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution. Br J Pharmacol, 2018, 175(23): 4353-4370

[5] Garrido-MesaJ, AlgieriF, Rodríguez-NogalesA, et al.. Immunomodulatory tetracyclines ameliorate DNBS-colitis: Impact on microRNA expression and microbiota composition. Biochem Pharmacol, 2018, 155: 524-536

[6] Garrido-MesaJ, AlgieriF, Rodriguez-NogalesA, et al.. A new therapeutic association to manage relapsing experimental colitis: Doxycycline plus Saccharomyces boulardii. Pharmacol Res, 2015, 97: 48-63

[7] Garrido-MesaN, CamuescoD, ArribasB, et al.. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol Res, 2011, 63(4): 308-319

[8] OhkusaT, NomuraT, TeraiT, et al.. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol, 2005, 40(11): 1334-1342

[9] OhkusaT, KatoK, TeraoS, et al.. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol, 2010, 105(8): 1820-1829

[10] TurnerD, LevineA, KolhoKL, et al.. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis, 2014, 8(11): 1464-1470

[11] KordyK, RomeoAC, LeeDJ, et al.. Combination antibiotics improves disease activity and alters microbial communities in children with ulcerative colitis. J Pediatr Gastroenterol Nutr, 2018, 67(3): e60-e63

[12] BretonJ, KastlA, HoffmannN, et al.. Efficacy of combination antibiotic therapy for refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis, 2019, 25(9): 1586-1593

[13] UeharaT, KatoK, OhkusaT, et al.. Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol, 2010, 25(Suppl 1): S62-66

[14] LabroMT. Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents. Expert Rev Anti Infect Ther, 2012, 10(3): 319-340

[15] AbarbanelDN, SekiSM, DaviesY, et al.. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol, 2013, 33(2): 397-406

[16] PradhanS, MadkeB, KabraP, et al.. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. Indian J Dermatol, 2016, 61(5): 469-481

[17] TanEE, QuahSY, BergenholtzG, et al.. Antibiotics used in regenerative endodontics modify immune response of macrophages to bacterial infection. J Endod, 2019, 45(11): 1349-1356

[18] AhmadH, VermaS, KumarVL. Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis. Inflamm Res, 2018, 67(2): 147-155

[19] WuH, XieS, YuJ, et al.. Pharmacokinetics and pharmacodynamics of levornidazole in patients with intra-abdominal anaerobic infection. Clin Ther, 2018, 40(9): 1548-1555

[20] LiuM, LiuX, WangL, et al.. TRPV4 inhibition improved myelination and reduced glia reactivity and inflammation in a cuprizone-induced mouse model of demyelination. Front Cell Neurosci, 2018, 12: 392

[21] LiuW, GuoW, WuJ, et al.. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol, 2013, 85(10): 1504-1512

[22] ParikhK, AntanaviciuteA, Fawkner-CorbettD, et al.. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature, 2019, 567(7746): 49-55

[23] WuXF, OuyangZJ, FengLL, et al.. Suppression of NF-κB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone. Toxicol Appl Pharmacol, 2014, 281(1): 146-156

[24] WasilewskaE, ZlotkowskaD, WroblewskaB. Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium-induced colitis. J Dairy Sci, 2019, 102(1): 37-53

[25] PierdomenicoM, PaloneF, CesiV, et al.. Transcription factor ZNF281: A novel player in intestinal inflammation and fibrosis. Front Immunol, 2018, 9: 2907

[26] ScheibeK, KerstenC, SchmiedA, et al.. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology, 2019, 156(4): 1082-1097 e11

[27] SongZM, LiuF, ChenYM, et al.. CTGF-mediated ERK signaling pathway influences the inflammatory factors and intestinal flora in ulcerative colitis. Biomed Pharmacother, 2019, 111: 1429-1437

[28] MaiCT, WuMM, WangCL, et al.. Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. Mol Immunol, 2019, 105: 76-85

[29] HiromuraM, NohtomiK, MoriY, et al.. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages. Biochem Biophys Res Commun, 2018, 495(1): 223-229

[30] LiuZ, WangL, DongZ, et al.. Heparin inhibits lipopolysaccharide-induced inflammation via inducing caveolin-1 and activating the p38/mitogen-activated protein kinase pathway in murine peritoneal macrophages. Mol Med Rep, 2015, 12(3): 3895-3901

[31] FengH, GuoL, SongZ, et al.. Caveolin-1 protects against sepsis by modulating inflammatory response, alleviating bacterial burden, and suppressing thymocyte apoptosis. J Biol Chem, 2010, 285(33): 25154-25160

[32] WangXM, KimHP, SongR, et al.. Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol, 2006, 34(4): 434-442

[33] HuJ, ZhangJ, WuS, et al.. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria. Int J Antimicrob Agents, 2014, 44(6): 514-519